Medical Decision Making in Multiple System Atrophy (MeDeMSA)
Multiple System Atrophy
About this trial
This is an interventional supportive care trial for Multiple System Atrophy focused on measuring MSA, Movement disorders, Autonomic dysfunctions, Telemedicine, Palliative care, Caregivers burden
Eligibility Criteria
Inclusion Criteria For individuals with MSA: i. Age ≥30 years at the time of consent; ii. Diagnosed with clinically probable or clinically established MSA according to the current MDS MSA criteria (1); iii. Life-expectancy of at least 24 months as assessed by the investigator at the time of consent; iv. Understands and agrees to comply with the study procedures and provides written informed consent (Note: a legal representative may NOT provide consent on behalf of the subject); v. Signed and dated informed consent document; vi. Fluency in German; vii. Living in Tyrol, if not able to walk or stand without assistance/support at the time of consent. For informal caregivers: i. Informal caregiver (i.e. person not receiving payment for his/her caregiving) of an individual with MSA recruited in the present study; ii. Life-expectancy of at least 24 months as assessed by the investigator at the time of consent; iii. Age≥ 18 years at the time of consent; iv. Understands and agrees to provide information as outlined in the study protocol and to engage in semi-structured online interviews; v. Provides signed and dated written informed consent; vi. Full legal capacity; vii. Fluency in German. Exclusion Criteria For individuals with MSA i. Participation in an interventional clinical study at screening and throughout the study that would interfere with the MeDeMSA Care personalized treatment plan or would not permit telemedicine and mobile palliative care strategies; ii. Charlson comorbidity index >4 at the time of consent; iii. Other major underlying medical conditions that may confound interpretation of study results as assessed by the investigator.
Sites / Locations
- Innsbruck Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Group 1
Group 2
Personalized best medical care.
Personalized best medical care PLUS telemedicine